NEWS RELEASE

Teijin to invest in U.S. Venture-capital FundTokyo, Japan, April 6, 2020 --- Teijin Limited announced today that it will invest up toapproximately 90 million U.S. dollars in the Medtech Convergence Fund (MCF), a
healthcare venture-capital fund managed by SV Health Investors.
SV Health Investors has partnered with the senior members of Norwich Ventures tocreate this new fund and build the portfolio.
SV Health Investors and Norwich Ventures have excellent reputations for investing inand nurturing Medtech startups. The MCF team will leverage their decades of operating
and investment experience to provide entrepreneurs with the financial support andstrategic guidance necessary for building a successful business.
Through investment and collaboration with its new partners, Teijin aims to acquire newtechnologies and develop new businesses in the healthcare field. In particular, MCF will
focus on regulated medical devices in less-intensive care settings, including in thehome.
Teijin’s decision to invest in the fund reflects the company’s vision of developing
disruptive, cost-saving healthcare solutions, which closely matches the vision of theMCF team.
Teijin’s medium- to long-term strategy for its healthcare business, as defined in its
Medium-Term Management Plan for 2020-2022 “ALWAYS EVOLVING”, envisions thedevelopment of community-based comprehensive healthcare solutions that willleverage the company’s expertise in pharmaceutical and home-healthcare businesses.
Teijin will focus on innovative healthcare products and services, including individualtreatments, to enable people to live healthier, happier and more fulfilling lives.
Medtech Convergence Fund
Fund Size
90 million U.S. dollars (including the GP commitment)
General partner: Medtech Convergence GP, LLC
Fund Partners
Limited partner: Teijin Limited
Headquarters
Boston, Massachusetts
Investment field
Medical devices and services in healthcare field
Investment targets
Early stage companies
Investment locations
Primarily U.S., Europe and Israel

Teijin will share employees with the fund to strengthen long-term collaboration aimed atdevelopment of healthcare businesses in international markets. In addition, throughparticipation in company incubation activities with its new partners, Teijin aims tostimulate its own research and development of medical devices and services based on
novel innovation models.
Healthcare solutions comprising products, services and digital technologies are
becoming increasingly vital worldwide, including in Japan where the population is aging
rapidly. Teijin is committed to providing superior products and specialized serves toenhance the quality of life of patients worldwide.
About the Medtech Convergence Fund
The Medtech Convergence Fund (MCF) is a seed and early-stage venture capital fundcommitted to helping entrepreneurs, healthcare professionals and inventors build
innovative medical technology companies. Our fund strategy is focused on theincreasing convergence of medical technology with software, telecommunications, andnew service models to create solutions to some of the most significant healthchallenges. MCF’s mission is to invest in therapeutic and monitoring technologies thatoffer superior patient outcomes while enabling better healthcare efficiency. The MCF
team leverages decades of medical device investing and operating experience to help
entrepreneurs succeed from the earliest phases of product development.
To learn more visit https://www.medtechconvergence.com
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in theareas of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Its main fields of operation are
high-performance fibers such as aramid, carbon fibers & composites, healthcare, films,
resin & plastic processing, polyester fibers, products converting and IT. The group hasover 170 companies and around 20,000 employees spread out over 20 countries
worldwide. It posted consolidated sales of JPY888.6 billion (USD 8.1 billion) and total
assets of JPY 1020.7 billion (USD 9.3 billion) in the fiscal year ending March 31, 2019.
Press Contact
Corporate Communications
Teijin Limited
pr@teijin.co.jp